DK3489366T3 - Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener - Google Patents

Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener Download PDF

Info

Publication number
DK3489366T3
DK3489366T3 DK18211367.0T DK18211367T DK3489366T3 DK 3489366 T3 DK3489366 T3 DK 3489366T3 DK 18211367 T DK18211367 T DK 18211367T DK 3489366 T3 DK3489366 T3 DK 3489366T3
Authority
DK
Denmark
Prior art keywords
transgenes
amplified
products
methods
cell lines
Prior art date
Application number
DK18211367.0T
Other languages
English (en)
Inventor
Derek Jantz
James Jefferson Smith
Michael G Nicholson
Original Assignee
Prec Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prec Biosciences Inc filed Critical Prec Biosciences Inc
Application granted granted Critical
Publication of DK3489366T3 publication Critical patent/DK3489366T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
    • C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
    • C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y105/00—Oxidoreductases acting on the CH-NH group of donors (1.5)
    • C12Y105/01—Oxidoreductases acting on the CH-NH group of donors (1.5) with NAD+ or NADP+ as acceptor (1.5.1)
    • C12Y105/01003—Dihydrofolate reductase (1.5.1.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK18211367.0T 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener DK3489366T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161492174P 2011-06-01 2011-06-01
EP12792301.9A EP2714936B1 (en) 2011-06-01 2012-06-01 Methods and products for producing engineered mammalian cell lines with amplified transgenes

Publications (1)

Publication Number Publication Date
DK3489366T3 true DK3489366T3 (da) 2020-02-24

Family

ID=47260412

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12792301.9T DK2714936T3 (da) 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener
DK18211367.0T DK3489366T3 (da) 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12792301.9T DK2714936T3 (da) 2011-06-01 2012-06-01 Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener

Country Status (5)

Country Link
US (5) US20140179005A1 (da)
EP (3) EP3683319A1 (da)
DK (2) DK2714936T3 (da)
ES (2) ES2773891T3 (da)
WO (1) WO2012167192A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116622704A (zh) * 2012-07-25 2023-08-22 布罗德研究所有限公司 可诱导的dna结合蛋白和基因组干扰工具及其应用
AU2015229299A1 (en) 2014-03-12 2016-09-22 Precision Biosciences, Inc. Dystrophin gene exon deletion using engineered nucleases
SG10201808811QA (en) 2014-04-10 2018-11-29 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Method and compositions for cellular immunotherapy
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
EP3209785B1 (en) 2014-10-23 2019-07-31 Regeneron Pharmaceuticals, Inc. Novel cho integration sites and uses thereof
US20180344817A1 (en) 2015-05-01 2018-12-06 Precision Biosciences, Inc. Precise deletion of chromosomal sequences in vivo and treatment of nucleotide repeat expansion disorders using engineered nucleases
MX2018001568A (es) 2015-08-07 2019-04-25 Seattle Children´S Hospital Dba Seattle Children´S Res Institute Celulas t biespecificas de receptor quimerico de antigeno (car) para focalizacion a tumores solidos.
CA2997909A1 (en) 2015-09-08 2017-03-16 Precision Biosciences, Inc. Treatment of retinitis pigmentosa using engineered meganucleases
WO2017051347A2 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
ES2768984T3 (es) 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
US20190017075A1 (en) 2015-12-23 2019-01-17 Precision Biosciences, Inc. Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
WO2017173043A1 (en) * 2016-03-30 2017-10-05 Spark Therapeutics, Inc. Cell line for recombinant protein and/or viral vector production
EP3448380B1 (en) 2016-04-27 2021-12-01 University Of Puerto Rico 1,5-disubstituted 1,2,3-triazoles are inhibitors of rac/cdc42 gtpases
EP3452583B1 (en) 2016-05-03 2021-10-27 Precision Biosciences, Inc. Engineered nucleases useful for treatment of hemophilia a
KR20230010826A (ko) 2016-10-14 2023-01-19 프리시젼 바이오사이언시스 인코포레이티드 B형 간염 바이러스 게놈 내의 인식 서열에 대해 특이적인 조작된 메가뉴클레아제
WO2018167621A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
EP4269596A3 (en) 2017-04-21 2024-02-14 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the pcsk9 gene
EP4775669A2 (en) 2017-06-30 2026-07-15 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
EP3704238B1 (en) 2017-11-01 2024-01-03 Precision Biosciences, Inc. Engineered nucleases that target human and canine factor viii genes as a treatment for hemophilia a
KR102617818B1 (ko) 2018-04-12 2023-12-27 프리시젼 바이오사이언시스 인코포레이티드 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
EP3898661A1 (en) 2018-12-21 2021-10-27 Precision BioSciences, Inc. Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
CN114026228A (zh) 2019-05-07 2022-02-08 精密生物科学公司 用于识别序列的工程化大范围核酸酶的优化
US20220273715A1 (en) * 2019-07-25 2022-09-01 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
EP4007814A1 (en) * 2019-07-26 2022-06-08 Akouos, Inc. Methods of treating hearing loss using a secreted target protein
EP4065709A4 (en) * 2019-11-25 2023-11-29 Baylor College of Medicine SELECTIVE EXPANSION OF GENE-TARGETED CELLS
US12410418B2 (en) 2019-12-06 2025-09-09 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US20230175014A1 (en) * 2020-04-27 2023-06-08 The Trustees Of The University Of Pennsylvania Compositions and methods for reducing nuclease expression and off-target activity using a promoter with low transcriptional activity
WO2021231259A1 (en) 2020-05-11 2021-11-18 Precision Biosciences, Inc. Self-limiting viral vectors encoding nucleases
EP4150068A1 (en) 2020-05-12 2023-03-22 Precision BioSciences, Inc. Treatment of retinitis pigmentosa using improved engineered meganucleases
US20240011003A1 (en) 2020-08-21 2024-01-11 Precision Biosciences, Inc. Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
KR20250099412A (ko) 2020-11-12 2025-07-01 프리시젼 바이오사이언시스 인코포레이티드 디스트로핀 유전자 내의 인식 서열에 대해 특이성을 갖는 조작된 메가뉴클레아제
CA3172161A1 (en) 2021-01-08 2022-07-14 James Jefferson Smith Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
WO2022226316A1 (en) 2021-04-22 2022-10-27 Precision Biosciences, Inc. Compositions and methods for generating male sterile plants
IL307834A (en) 2021-04-22 2023-12-01 Prec Biosciences Inc Transgenic meganonucleases targeting human mitochondrial genomes
US12134776B2 (en) * 2021-10-06 2024-11-05 G&P Bioscience Co., Ltd. Development of optimized recombinant expression construct
AU2022368911A1 (en) 2021-10-19 2024-05-30 Precision Biosciences, Inc. Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
MX2024004812A (es) 2021-10-19 2024-07-15 Prec Biosciences Inc Métodos de edición génica para el tratamiento de la deficiencia de alfa-1 antitripsina (aat).
WO2025101946A1 (en) 2023-11-08 2025-05-15 Precision Biosciences, Inc. Polypeptide linkers for use in engineered meganucleases
WO2025233894A1 (en) 2024-05-09 2025-11-13 University Of Miami Engineered meganucleases that target human mitochondrial genomes
WO2026028165A1 (en) 2024-08-01 2026-02-05 Precision Biosciences, Inc. Engineered meganucleases having specificity for recognition sequences in the c9orf72 gene
CN119753013A (zh) * 2024-11-25 2025-04-04 杭州宏望医学检验实验室有限公司 一种适用于自身抗体检测的cho细胞株的构建及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156304A (en) 1990-12-20 2000-12-05 University Of Pittsburgh Of The Commonwealth System Of Higher Education Gene transfer for studying and treating a connective tissue of a mammalian host
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
US7338800B2 (en) * 2002-01-16 2008-03-04 Baylor College Of Medicine In vivo gene transfer
WO2009095742A1 (en) 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20060206949A1 (en) * 2003-01-28 2006-09-14 Sylvain Arnould Custom-made meganuclease and use thereof
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
EP2019860A4 (en) * 2006-05-22 2010-12-15 Hiprocell Llc PROTEIN PRODUCTION USING EUKARYOTIC CELL LINES
WO2008059317A1 (en) 2006-11-14 2008-05-22 Cellectis Meganuclease variants cleaving a dna target sequence from the hprt gene and uses thereof
FR2910490B1 (fr) * 2006-12-20 2012-10-26 Lab Francais Du Fractionnement Lignee cellulaire a forte activite transcriptionnelle pour la production de proteines, notamment therapeutiques
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
WO2009076292A2 (en) 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in dnase hypersensitive regions of the human genome
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US9273296B2 (en) * 2008-09-08 2016-03-01 Cellectis Meganuclease variants cleaving a DNA target sequence from a glutamine synthetase gene and uses thereof
EP2180058A1 (en) * 2008-10-23 2010-04-28 Cellectis Meganuclease recombination system

Also Published As

Publication number Publication date
ES2713529T3 (es) 2019-05-22
WO2012167192A3 (en) 2014-05-08
EP2714936B1 (en) 2018-12-12
US20140179005A1 (en) 2014-06-26
EP2714936A2 (en) 2014-04-09
EP2714936A4 (en) 2015-07-29
EP3683319A1 (en) 2020-07-22
ES2773891T3 (es) 2020-07-15
US20190249199A1 (en) 2019-08-15
US9822381B2 (en) 2017-11-21
US20160017372A1 (en) 2016-01-21
US20180163233A1 (en) 2018-06-14
WO2012167192A2 (en) 2012-12-06
EP3489366A1 (en) 2019-05-29
DK2714936T3 (da) 2019-03-25
EP3489366B1 (en) 2019-12-25
US20220333137A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
DK2872629T3 (da) Tm-forstærkede blokeringsoligonukleotider og lokkemidler til forbedret target-berigesle og reduceret off-target-udvælgelse
DK3045187T3 (da) Injektor og fremgangsmåde til samling
DK2756073T3 (da) Manipuleret væv til in vitro-forskningsanvendelser, anordninger deraf og fremgangsmåder til fremstilling deraf
DK3468197T3 (da) Fremgangsmåde til interforudsigelse og indretning dertil
DK2950535T3 (da) Fremgangsmåde og indretning til at afkode intra-forudsigelsestilstand
EP2880054A4 (en) HLA-G-MODIFIED CELLS AND METHOD
DK3257943T3 (da) Fremgangsmåder og vektorer til celleimmortalisering
DK3482765T3 (da) Langtidsvirkende væksthormon og fremgangsmåder til produktion deraf
DK3308641T3 (da) Immundeficient genmodificeret gnaver og fremgangsmåder til anvendelse deraf
DK2678283T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til deres fremstilling
PL3863288T3 (pl) Sposoby intra-predykcji i środek nośnikowy
DK2794907T3 (da) Fremgangsmåder og materialer til vurdering af tab af heterozygositet
DK2758349T3 (da) Vanadiumbaserede frittematerialer og fremgangsmåder til fremstilling heraf
DK2528180T3 (da) Metoder og systemer til jævnstrøms-energitransmission
DK2794850T3 (da) Bioteknologisk produktion af alkoholer og derivater deraf
DK2506416T3 (da) System og fremgangsmåde til strømkonvertering
DK3489685T3 (da) Signalforstærkning i sidestrømning og tilsvarende immunoassays
DK3578201T3 (da) Fremgangsmåder og sammensætninger til naturlige dræberceller
DK2867600T3 (da) System og fremgangsmåde til carbondioxidopfangning og -deponering
DK2915064T3 (da) Fremgangsmåde til at indikere tilstedeværelsen af gashydrat og overfladegas i et undervandsmiljø
IL230469A0 (en) Curable compositions and membranes
DK2521221T4 (da) Høreanordning og fremgangsmåde
DK2744456T3 (da) Forbedringer ved eller i forbindelse med proteser og ortoser
DK3415157T3 (da) N-acyldipeptidderivater og anvendelser deraf
DK2925782T3 (da) Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf